文献速递主动脉疾病

他汀类药物治疗与腹主动脉瘤修复术后长期生存率较高相关,但与围手术期生存率无关

Statin therapy is associated with higher long-term but not perioperative survival after abdominal aortic aneurysm repair.
PubMed 文献 · J Vasc Surg · 2018-03-23

基于血管质量倡议登记研究,纳入2003至2017年37950例腹主动脉瘤修复患者,经倾向评分加权分析发现,术前他汀治疗与30天死亡及院内卒中或心肌梗死无关,但与更高的1年(94% vs 90%)和5年(85% vs 81%)生存率相关;术前未用他汀者出院前启用他汀与更高的1年和5年生存率相关。

要点

  • 术前他汀治疗与腹主动脉瘤修复术后30天死亡及院内卒中或心肌梗死无关。
  • 术前他汀治疗者1年生存率94% vs 90%,5年生存率85% vs 81%(P<.001)。
  • 术前未用他汀者出院前启用他汀,1年生存率94% vs 91%,5年生存率89% vs 81%(P<.001)。

核心结论

  • 术前他汀治疗与腹主动脉瘤修复术后长期生存率较高相关,但与围手术期死亡率和并发症无关。
  • 在既往未使用他汀的患者中,启用他汀治疗与生存率显著较高相关。
  • 作者认为,所有无禁忌症的腹主动脉瘤患者均应接受他汀治疗。
  • 作者建议,腹主动脉瘤修复时未服用他汀的患者,临床医生应考虑在出院前启用他汀。

研究设计与样本

  • 基于血管质量倡议登记研究,纳入2003至2017年接受腹主动脉瘤修复且无他汀不耐受记录的患者。
  • 共识别40452例腹主动脉瘤修复,其中37950例符合入组标准(29257例腔内修复,8693例开放修复)。
  • 采用倾向评分和逆概率加权处理非随机治疗分配。

主要发现

  • 总体25997例(69%)术前服用他汀,腔内修复者较开放修复者更常服用他汀(69% vs 66%;P<.001)。
  • 倾向加权后,术前他汀治疗与30天死亡或院内卒中或心肌梗死无关。
  • 术前他汀治疗者自手术日期起调整后1年生存率94% vs 90%,5年生存率85% vs 81%(总体P<.001),亚组分析显示仅适用于完整或症状性动脉瘤。
  • 术前未服用他汀且存活出院的11941例中,2910例(24%)在出院前启用他汀。
  • 术前未用他汀者中,出院前启用他汀者1年生存率94% vs 91%,5年生存率89% vs 81%(总体P<.001),破裂患者绝对长期生存差异最大(87% vs 62%;总体P<.001)。

临床怎么用

  • 作者认为,所有无禁忌症的腹主动脉瘤患者均应接受他汀治疗。
  • 作者建议,腹主动脉瘤修复时未服用他汀的患者,临床医生应考虑在出院前启用他汀。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although preoperative and perioperative statin therapy improves postoperative outcomes in several populations, few data examine its association with survival after abdominal aortic aneurysm (AAA) repair. In addition, no data exist regarding the benefits of starting statins in patients with AAA not currently taking them. METHODS: We performed a registry-based study of all patients undergoing repair of AAAs in the Vascular Quality Initiative between 2003 and 2017 without documented statin intolerance. In our primary analysis, we evaluated the association between preoperative statin therapy and long-term mortality, 30-day mortality, and in-hospital myocardial infarction and stroke. As a secondary analysis, we studied the cohort of patients not taking a statin preoperatively and compared their long-term mortality on the basis of whether they were discharged on a statin. To account for nonrandom assignment to treatment, we constructed propensity scores and applied inverse probability weighting. RESULTS: We identified 40,452 AAA repairs, of which 37,950 fit our entry criteria (29,257 endovascular and 8693 open). Overall, 25,997 patients (69%) were taking a statin preoperatively, with patients undergoing endovascular aneurysm repair more frequently taking a statin than those undergoing open repair (69% compared with 66%; P < .001). After propensity weighting, preoperative statin therapy was not associated with 30-day death or in-hospital stroke or myocardial infarction. However, patients taking statins preoperatively experienced higher adjusted 1-year (94% vs 90%) and 5-year (85% vs 81%) survival from the date of surgery compared with those who were not (P < .001 overall), although subgroup analysis showed that this applied only to intact or symptomatic aneurysms. Of the 11,941 patients not taking a statin preoperatively and discharged alive, 2910 (24%) started on a statin before discharge. In our secondary analysis of the subset of patients not taking statins preoperatively, those initiated on a statin before discharge experienced higher survival at 1 year (94% vs 91%) and 5 years (89% vs 81%; P < .001 overall) than those who remained off statin therapy, with the greatest absolute long-term survival difference in patients with rupture (87% vs 62%; P < .001 overall). CONCLUSIONS: Preoperative statin therapy is associated with higher long-term survival but not perioperative mortality and morbidity in patients undergoing AAA repair, and initiating statin therapy in previously statin-naive patients is associated with markedly higher survival. All patients with AAAs without contraindications should receive statin therapy. In patients not taking a statin at the time of AAA repair, clinicians should consider initiating one before discharge.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. O'Donnell TFX, Deery SE, Shean KE, et al. Statin therapy is associated with higher long-term but not perioperative survival after abdominal aortic aneurysm repair. J Vasc Surg. 2018. PMID: 29580855. doi:10.1016/j.jvs.2017.11.084

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。